secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001213900-25-121374
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences authorized shares increased from 20M to 1B; officer exculpation rejected
--------------------------------------------------------------------------------

- Authorized common shares increased from 20M to 1B via Certificate of Amendment effective Dec 10, 2025.
- Stockholders rejected officer exculpation amendment (358,746 for, 63,603 against, 3,587 abstain).
- Second Amendment to 2016 Omnibus Incentive Plan approved (406,837 for, 15,223 against).
- Four director nominees elected with >418K votes each; RBSM LLP ratified as auditor (680,031 for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390025121374/0001213900-25-121374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390025121374/ea0269386-8k_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-121374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer